Frontline Combination Approaches for Metastatic RCC
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.
EP: 1.Frontline Combination Approaches for Metastatic RCC
EP: 2.Personal Approaches to Frontline Therapy for Metastatic RCC
EP: 3.The Phase 3 CLEAR Study in Metastatic RCC
EP: 4.Metastatic RCC: Frontline TKI/IO Safety Data
EP: 5.Implications for Treating Metastatic RCC With TKI/I-O Regimens Upfront
EP: 6.Risk Scoring Systems for Metastatic RCC
EP: 7.Future Use of Novel Combinations for Metastatic RCC Treatment
EP: 8.Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma
Toni Choueiri, MD: For the past year or two and most recently at the Genitourinary Cancers Symposium, we are having an explosion of first-line options in this disease [metastatic renal cell carcinoma]. It is something quite refreshing. The combination of nivolumab and ipilimumab is the only IO [immunotherapy]/IO combination. After multiple cutoffs of the data and follow-up to 4 years, we’re seeing a hazard ratio for survival of 0.6, so stable. This is an option that is illustrated by the NCCN [National Comprehensive Cancer Network] guidelines as a first-line option. Now we are seeing more options coming along. The combination of pembrolizumab and axitinib does have an overall survival after several data cuts, and it is also a preferred regimen, both in [patients with ] favorable and intermediate-poor risk.
The nivolumab and ipilimumab combination is in poor and intermediate only.More recently the option of cabozantinib and nivolumab is also a preferred first-line option in both the favorable and the poor and intermediate, based on the CheckMate 9ER trial. This regimen was approved in January of 2021. There are other recommended regimens, some of them are combinations, some are as a single agent, but these are the most important frontline ones illustrated by the NCCN guidelines.
Transcript edited for clarity.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
